Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data

Current guidelines recommend dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 inhibitors following percutaneous coronary intervention (PCI). CYP2C19 genotype can guide DAPT selection, prescribing ticagrelor or prasugrel for loss-of-function (LOF) allele carriers (genotype-guided es...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacogenomics J
Main Authors: Limdi, Nita A., Cavallari, Larisa H., Lee, Craig R., Hillegass, William B., Holmes, Ann M., Skaar, Todd C., Pisu, Maria, Dillon, Chrisly, Beitelshees, Amber L., Empey, Philip E., Duarte, Julio D., Diaby, Vakaramoko, Gong, Yan, Johnson, Julie A., Graves, John, Garbett, Shawn, Zhou, Zilu, Peterson, Josh F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7417282/
https://ncbi.nlm.nih.gov/pubmed/32042096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41397-020-0162-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados